CN110286215A - 用于进行多路测定法的改进方法 - Google Patents
用于进行多路测定法的改进方法 Download PDFInfo
- Publication number
- CN110286215A CN110286215A CN201910389701.1A CN201910389701A CN110286215A CN 110286215 A CN110286215 A CN 110286215A CN 201910389701 A CN201910389701 A CN 201910389701A CN 110286215 A CN110286215 A CN 110286215A
- Authority
- CN
- China
- Prior art keywords
- seq
- seqidno
- oligonucleotides
- agent
- binding reagents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract description 129
- 238000000691 measurement method Methods 0.000 title abstract description 10
- 239000012491 analyte Substances 0.000 claims abstract description 173
- 239000007790 solid phase Substances 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 721
- 230000027455 binding Effects 0.000 claims description 586
- 238000009739 binding Methods 0.000 claims description 586
- 239000003153 chemical reaction reagent Substances 0.000 claims description 470
- 230000008685 targeting Effects 0.000 claims description 456
- 108091034117 Oligonucleotide Proteins 0.000 claims description 346
- 230000000295 complement effect Effects 0.000 claims description 289
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 264
- 238000005259 measurement Methods 0.000 claims description 93
- 239000013589 supplement Substances 0.000 claims description 89
- 238000001514 detection method Methods 0.000 claims description 75
- 239000002245 particle Substances 0.000 claims description 65
- 108010090804 Streptavidin Proteins 0.000 claims description 56
- 239000004615 ingredient Substances 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 26
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
- 108090001008 Avidin Proteins 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 14
- -1 amino, mercapto Chemical class 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 7
- 125000003368 amide group Chemical group 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 238000000159 protein binding assay Methods 0.000 abstract description 17
- 230000003993 interaction Effects 0.000 abstract description 13
- 230000009871 nonspecific binding Effects 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 description 200
- 239000000523 sample Substances 0.000 description 103
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 87
- 239000000203 mixture Substances 0.000 description 51
- 235000020958 biotin Nutrition 0.000 description 49
- 239000011616 biotin Substances 0.000 description 45
- 229960002685 biotin Drugs 0.000 description 45
- 238000002156 mixing Methods 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 37
- 239000002585 base Substances 0.000 description 31
- 239000003085 diluting agent Substances 0.000 description 24
- 230000004048 modification Effects 0.000 description 24
- 238000012986 modification Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 239000002253 acid Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 238000004020 luminiscence type Methods 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 230000009260 cross reactivity Effects 0.000 description 19
- 239000003446 ligand Substances 0.000 description 19
- 230000003278 mimic effect Effects 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 238000003018 immunoassay Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 230000001502 supplementing effect Effects 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 230000002788 anti-peptide Effects 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000218636 Thuja Species 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 238000000149 argon plasma sintering Methods 0.000 description 7
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 125000003835 nucleoside group Chemical group 0.000 description 7
- 238000002966 oligonucleotide array Methods 0.000 description 7
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 150000001345 alkine derivatives Chemical class 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001615 biotins Chemical class 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000005482 chemotactic factor Substances 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 239000011499 joint compound Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 108091023037 Aptamer Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000007413 biotinylation Methods 0.000 description 5
- 230000006287 biotinylation Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 4
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- 102100031013 Transgelin Human genes 0.000 description 4
- 238000002820 assay format Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000606153 Chlamydia trachomatis Species 0.000 description 3
- 108090000056 Complement factor B Proteins 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 150000003949 imides Chemical class 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000012898 sample dilution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 241001136175 Burkholderia pseudomallei Species 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 241001619326 Cephalosporium Species 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000150562 Hantaan orthohantavirus Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 241000351643 Metapneumovirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241001279361 Stachybotrys Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- 241000223259 Trichoderma Species 0.000 description 2
- 241000224527 Trichomonas vaginalis Species 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 241000710951 Western equine encephalitis virus Species 0.000 description 2
- 241000353223 Xenopsylla cheopis Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000001745 anti-biotin effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940065181 bacillus anthracis Drugs 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 235000019846 buffering salt Nutrition 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 210000002309 caveolated cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000005518 electrochemistry Effects 0.000 description 2
- 238000007519 figuring Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007650 screen-printing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 208000021510 thyroid gland disease Diseases 0.000 description 2
- 230000001646 thyrotropic effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NGNQZCDZXSOVQU-UHFFFAOYSA-N 8,16,18,26,34,36-hexahydroxyhentetracontane-2,6,10,14,24,28,32-heptone Chemical compound CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCC(C)=O NGNQZCDZXSOVQU-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 101000939689 Araneus ventricosus U2-aranetoxin-Av1a Proteins 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 101000633673 Buthacus arenicola Beta-insect depressant toxin BaIT2 Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 101000654318 Centruroides noxius Beta-mammal toxin Cn2 Proteins 0.000 description 1
- 101001028695 Chironex fleckeri Toxin CfTX-2 Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102100024607 DNA topoisomerase 1 Human genes 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000830681 Homo sapiens DNA topoisomerase 1 Proteins 0.000 description 1
- 101000574013 Homo sapiens Pre-mRNA-processing factor 40 homolog A Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 241000223251 Myrothecium Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102100025822 Pre-mRNA-processing factor 40 homolog A Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241001264154 Verticimonosporium Species 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 108010036226 antigen CYFRA21.1 Proteins 0.000 description 1
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000013433 optimization analysis Methods 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108010041201 prothrombin fragment 1 Proteins 0.000 description 1
- 108010041206 prothrombin fragment 2 Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012493 sandwich binding assay Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000010897 surface acoustic wave method Methods 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 208000014016 variola minor infection Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
- B01L3/50853—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates with covers or lids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/021—Identification, e.g. bar codes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/043—Hinged closures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0609—Holders integrated in container to position an object
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
- G01N2470/04—Sandwich assay format
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Clinical Laboratory Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775860P | 2013-03-11 | 2013-03-11 | |
| US61/775860 | 2013-03-11 | ||
| US201361778727P | 2013-03-13 | 2013-03-13 | |
| US61/778727 | 2013-03-13 | ||
| CN201480026770.1A CN105378477B9 (zh) | 2013-03-11 | 2014-03-11 | 用于进行多路测定法的改进方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480026770.1A Division CN105378477B9 (zh) | 2013-03-11 | 2014-03-11 | 用于进行多路测定法的改进方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110286215A true CN110286215A (zh) | 2019-09-27 |
Family
ID=51488514
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910389701.1A Pending CN110286215A (zh) | 2013-03-11 | 2014-03-11 | 用于进行多路测定法的改进方法 |
| CN201480026770.1A Active CN105378477B9 (zh) | 2013-03-11 | 2014-03-11 | 用于进行多路测定法的改进方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480026770.1A Active CN105378477B9 (zh) | 2013-03-11 | 2014-03-11 | 用于进行多路测定法的改进方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (13) | US10189023B2 (enExample) |
| EP (2) | EP2972353B1 (enExample) |
| JP (1) | JP6791750B2 (enExample) |
| KR (4) | KR102746751B1 (enExample) |
| CN (2) | CN110286215A (enExample) |
| AU (3) | AU2014249190C1 (enExample) |
| CA (2) | CA2904020C (enExample) |
| DK (1) | DK2972353T3 (enExample) |
| ES (1) | ES2942031T3 (enExample) |
| WO (1) | WO2014164594A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904020C (en) * | 2013-03-11 | 2022-06-14 | Meso Scale Technologies, Llc. | Improved methods for conducting multiplexed assays |
| US9618510B2 (en) | 2013-03-13 | 2017-04-11 | Meso Scale Technologies, Llc. | Assay methods |
| CA2919833A1 (en) | 2013-07-30 | 2015-02-05 | President And Fellows Of Harvard College | Quantitative dna-based imaging and super-resolution imaging |
| KR102497054B1 (ko) | 2014-05-15 | 2023-02-06 | 메소 스케일 테크놀러지즈, 엘엘시 | 개선된 분석 방법 |
| CN116832890A (zh) | 2015-04-06 | 2023-10-03 | 中尺度技术有限责任公司 | 操作测定系统的方法及ecl免疫测定系统 |
| US10723988B2 (en) | 2015-04-22 | 2020-07-28 | Berkeley Lights, Inc. | Microfluidic cell culture |
| WO2017011560A1 (en) | 2015-07-15 | 2017-01-19 | Hycor Biomedical, Llc. | Customizable instrument |
| JP6858744B2 (ja) | 2015-08-07 | 2021-04-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | タンパク質−タンパク質相互作用の超分解能イメージング |
| US10799865B2 (en) | 2015-10-27 | 2020-10-13 | Berkeley Lights, Inc. | Microfluidic apparatus having an optimized electrowetting surface and related systems and methods |
| USD882818S1 (en) * | 2016-03-18 | 2020-04-28 | Meso Scale Technologies, Llc. | Reagent rack |
| USD1006251S1 (en) * | 2016-03-18 | 2023-11-28 | Meso Scale Technologies, Llc. | Rack and label |
| USD889685S1 (en) | 2016-03-18 | 2020-07-07 | Meso Scale Technologies, Llc. | Reagent rack cover |
| SG11201809539RA (en) | 2016-05-26 | 2018-12-28 | Berkeley Lights Inc | Covalently modified surfaces, kits, and methods of preparation and use |
| WO2018017949A1 (en) | 2016-07-22 | 2018-01-25 | Verily Life Sciences Llc | Quantitative massively parallel proteomics |
| WO2018025046A2 (en) * | 2016-08-05 | 2018-02-08 | Nn Scientific Limited | Device |
| US10618717B2 (en) * | 2017-07-31 | 2020-04-14 | Argos Technology, Inc. | Cryogenic storage box |
| WO2019069372A1 (ja) * | 2017-10-03 | 2019-04-11 | 株式会社ニコン | 検出対象の測定方法、捕捉プローブ固定化担体、検出キット、及び流体デバイス |
| EP4372383A3 (en) * | 2017-10-23 | 2024-11-06 | Nautilus Subsidiary, Inc. | Methods and systems for protein identification |
| EA202091646A1 (ru) * | 2018-01-05 | 2020-11-17 | Квошент Сюисс Са | Платформа на основе самособирающегося диагностического массива |
| EP3756009B1 (en) | 2018-02-23 | 2023-09-06 | Meso Scale Technologies, LLC | Methods of screening antigen-binding molecules by normalizing for the concentration of antigen-binding molecule |
| US11039856B2 (en) | 2018-05-10 | 2021-06-22 | Verily Life Sciences Llc | Surgical laparoscopic ports for implanting medical systems |
| WO2019222708A2 (en) | 2018-05-17 | 2019-11-21 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| US10936163B2 (en) | 2018-07-17 | 2021-03-02 | Methodical Mind, Llc. | Graphical user interface system |
| US20210382043A1 (en) | 2018-10-23 | 2021-12-09 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| US20220011301A1 (en) * | 2018-11-16 | 2022-01-13 | Roche Diagnostics Operations, Inc. | Streptavidin-coated solid phases with a member of a binding pair |
| WO2020104397A1 (en) | 2018-11-19 | 2020-05-28 | Bioaster | Methods and reagents for multiplex binding experiments |
| GB2579810B (en) * | 2018-12-14 | 2023-04-26 | Aeirtec Ltd | Assay Analysis |
| CA3132154A1 (en) * | 2019-03-01 | 2020-09-10 | Meso Scale Technologies, Llc. | Electrochemiluminescent labeled probes for use in immunoassay methods, methods using such and kits comprising same |
| SG11202111871WA (en) | 2019-05-03 | 2021-11-29 | Meso Scale Technologies Llc | Kits for detecting one or more target nucleic acid analytes in a sample and methods of making and using the same |
| AU2020380282A1 (en) | 2019-11-05 | 2022-05-26 | Meso Scale Technologies, Llc. | Methods and kits for quantitating radiation exposure |
| WO2021108666A2 (en) | 2019-11-26 | 2021-06-03 | Meso Scale Technologies, Llc. | Methods and kits for detecting autoimmune diseases |
| EP4143576A1 (en) | 2020-05-01 | 2023-03-08 | Meso Scale Technologies, LLC | Viral serology assays |
| WO2022020234A2 (en) * | 2020-07-20 | 2022-01-27 | Bio-Rad Laboratories, Inc. | Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor |
| US11434525B2 (en) | 2020-08-06 | 2022-09-06 | Singular Genomics Systems, Inc. | Spatial sequencing |
| US11492662B2 (en) * | 2020-08-06 | 2022-11-08 | Singular Genomics Systems, Inc. | Methods for in situ transcriptomics and proteomics |
| AU2021338303A1 (en) | 2020-09-02 | 2023-04-20 | Meso Scale Technologies, Llc | Kits for detecting one or more target analytes in a sample and methods of making and using the same |
| WO2022051481A2 (en) | 2020-09-04 | 2022-03-10 | Meso Scale Technologies, Llc. | Methods for isolating central nervous system surface marker displaying agents |
| KR20230130683A (ko) | 2021-01-11 | 2023-09-12 | 메소 스케일 테크놀러지즈, 엘엘시 | 검정 시스템 교정 시스템 및 방법 |
| EP4302089A1 (en) | 2021-03-01 | 2024-01-10 | Meso Scale Technologies, LLC | System and method for conducting a multiplexed assay |
| WO2022231900A1 (en) | 2021-04-26 | 2022-11-03 | Meso Scale Technologies, Llc. | Methods for isolating and analyzing a target analyte encapsulated by a surface marker displaying agent |
| EP4334706A4 (en) | 2021-05-05 | 2025-08-06 | Singular Genomics Systems Inc | MULTIOMICS ANALYSIS DEVICE AND METHODS OF USE THEREOF |
| WO2022246215A1 (en) | 2021-05-21 | 2022-11-24 | Meso Scale Technologies, Llc. | Viral strain serology assays |
| CA3225576A1 (en) | 2021-06-28 | 2023-01-05 | Meso Scale Technologies, Llc. | Methods, compositions, and kits for assay signal amplification |
| CN118265967A (zh) | 2021-07-21 | 2024-06-28 | 方法思维有限责任公司 | 图形用户界面系统引导模块 |
| US20250362296A1 (en) | 2022-06-17 | 2025-11-27 | Meso Scale Technologies, Llc. | Viral strain serology assays |
| EP4591062A1 (en) | 2022-09-23 | 2025-07-30 | Meso Scale Technologies, LLC | Orthopoxvirus serology assays |
| EP4638775A1 (en) | 2022-12-20 | 2025-10-29 | Meso Scale Technologies, LLC | Assay methods and kits |
| KR20250141160A (ko) | 2023-01-09 | 2025-09-26 | 메쏘디컬 마인드, 엘엘씨. | 품질 관리를 위한 그래픽 사용자 인터페이스 시스템 |
| KR20250154387A (ko) | 2023-01-25 | 2025-10-28 | 메쏘디컬 마인드, 엘엘씨. | 실험실 조정 장치, 방법, 및 시스템 |
| WO2024242845A1 (en) | 2023-05-24 | 2024-11-28 | Meso Scale Technologies, Llc. | Methods for assessing colorectal cancer using extracellular vesicles |
| WO2024249961A1 (en) | 2023-06-01 | 2024-12-05 | Singular Genomics Systems, Inc. | Methods and probes for detecting polynucleotide sequences in cells and tissues |
| WO2025049305A1 (en) | 2023-08-25 | 2025-03-06 | Meso Scale Technologies, Llc. | Viral strain serology assays |
| WO2025188949A1 (en) | 2024-03-08 | 2025-09-12 | Meso Scale Technologies, Llc. | Methods of quantifying analytes |
| WO2025260043A1 (en) | 2024-06-14 | 2025-12-18 | Meso Scale Technologies, Llc. | Methods and kits for measuring three or more tau epitopes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101208437A (zh) * | 2003-12-12 | 2008-06-25 | 圣路易斯大学 | 检测大分子和其它分析物的生物传感器 |
| CN101952719A (zh) * | 2007-07-27 | 2011-01-19 | 通信改革公司 | 检测测定法及其用途 |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4161515A (en) | 1973-10-02 | 1979-07-17 | Syva Company | Double receptor fluorescent immunoassay |
| US4604263A (en) * | 1976-06-17 | 1986-08-05 | Analytical Products, Inc. | Cell for gas sample equilibrator |
| US4139346A (en) | 1977-11-28 | 1979-02-13 | Enzo Bio Chem Incorporated | Nucleic acid and protein binding paper |
| FI56750C (fi) | 1978-02-27 | 1980-03-10 | Reijo Vihko | Rekationskaerl foer engaongsbruk vid immunologiskt bestaemning |
| IL55816A (en) | 1978-10-30 | 1982-04-30 | Ames Yissum Ltd | Method for simultaneous immunoassay of several different antibodies and a kit therefor |
| US4378344A (en) | 1979-09-28 | 1983-03-29 | Ventrex Laboratories, Inc. | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system |
| US4514508A (en) | 1982-07-06 | 1985-04-30 | Biond Inc. | Assaying for a multiplicity of antigens or antibodies with a detection compound |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| AU3844485A (en) | 1984-02-09 | 1985-08-15 | Enzo Biochem Inc. | Heterologous detection of cabeled dna |
| US4748111A (en) | 1984-03-12 | 1988-05-31 | Molecular Diagnostics, Inc. | Nucleic acid-protein conjugate used in immunoassay |
| CA1260372A (en) | 1984-04-27 | 1989-09-26 | Elazar Rabbani | Hybridization method for the detection of genetic materials |
| US5288609A (en) | 1984-04-27 | 1994-02-22 | Enzo Diagnostics, Inc. | Capture sandwich hybridization method and composition |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US5310687A (en) | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| JPH0823558B2 (ja) | 1984-11-27 | 1996-03-06 | オ−ジエニクス リミテツド | 検定装置 |
| JPH076984B2 (ja) | 1985-05-31 | 1995-01-30 | 株式会社日立製作所 | 複数項目分析方法 |
| US6165729A (en) | 1986-04-30 | 2000-12-26 | Hyperion Catalysis International, Inc. | Electrochemiluminescent reaction utilizing amine-derived reductant |
| US5591581A (en) | 1986-04-30 | 1997-01-07 | Igen, Inc. | Electrochemiluminescent rhenium moieties and methods for their use |
| US5147806A (en) | 1988-04-29 | 1992-09-15 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescence measurements |
| US5849478A (en) | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| US5750338A (en) | 1986-10-23 | 1998-05-12 | Amoco Corporation | Target and background capture methods with amplification for affinity assays |
| US4870003A (en) | 1987-06-15 | 1989-09-26 | Coulter Corporation | Simultaneous enzyme immunoassay for detecting antigen and/or antibody in humans |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| US5308754A (en) | 1988-03-21 | 1994-05-03 | Kankare Jouko J | Electrogenerated luminescence in solution |
| US5354655A (en) | 1988-03-29 | 1994-10-11 | Biocontrol Systems, Inc. | Method for determining the presence or concentration of a bound enzyme |
| US5093268A (en) | 1988-04-28 | 1992-03-03 | Igen, Inc. | Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena |
| US5705402A (en) | 1988-11-03 | 1998-01-06 | Igen International, Inc. | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| US6448091B1 (en) | 1988-11-03 | 2002-09-10 | Igen International, Inc. | Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection |
| CA2049036A1 (en) | 1989-03-21 | 1990-09-22 | Izak Bahar | Simultaneous dual analyte assay |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US6406844B1 (en) | 1989-06-07 | 2002-06-18 | Affymetrix, Inc. | Very large scale immobilized polymer synthesis |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| CA2022518A1 (en) | 1989-08-04 | 1991-02-05 | Richard P. Watts | Heterogeneous binding assays |
| US5719063A (en) | 1989-08-25 | 1998-02-17 | Boehringer Mannheim Corporation | Multiplex immunoassay system |
| US5324457A (en) | 1989-10-02 | 1994-06-28 | Board Of Regents, The University Of Tx System | Devices and methods for generating electrogenerated chemiluminescence |
| US5629153A (en) | 1990-01-10 | 1997-05-13 | Chiron Corporation | Use of DNA-dependent RNA polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
| CA2076349A1 (en) | 1990-02-22 | 1991-08-23 | Ashraf A. Ismail | Solid-phase interferometric immunoassay system |
| US5143852A (en) | 1990-09-14 | 1992-09-01 | Biosite Diagnostics, Inc. | Antibodies to ligand analogues and their utility in ligand-receptor assays |
| US5776672A (en) | 1990-09-28 | 1998-07-07 | Kabushiki Kaisha Toshiba | Gene detection method |
| US5726064A (en) | 1990-11-22 | 1998-03-10 | Applied Research Systems Ars Holding Nv | Method of assay having calibration within the assay |
| ZA92804B (en) | 1991-02-06 | 1992-12-30 | Igen Inc | Methods and apparatus for improved luminescence assays |
| JPH0534345A (ja) | 1991-02-19 | 1993-02-09 | Tdk Corp | 化学発光を利用する抗原・抗体の測定方法 |
| US5877028A (en) | 1991-05-29 | 1999-03-02 | Smithkline Diagnostics, Inc. | Immunochromatographic assay device |
| US5665539A (en) | 1991-07-12 | 1997-09-09 | The Regents Of The University Of California | Immuno-polymerase chain reaction system for antigen detection |
| AU2348092A (en) | 1991-07-16 | 1993-02-23 | Transmed Biotech Incorporated | Methods and compositions for simultaneous analysis of multiple analytes |
| EP0773227A1 (en) | 1991-09-18 | 1997-05-14 | Affymax Technologies N.V. | Diverse collections of oligomers in use to prepare drugs, diagnostic reagents, pesticides or herbicides |
| JP3097866B2 (ja) | 1991-10-15 | 2000-10-10 | マルティライト リミティド | 標識試薬を使用した結合検定法 |
| ZA929351B (en) | 1991-12-11 | 1993-06-04 | Igen Inc | Electrochemiluminescent label for DNA assays. |
| US5464746A (en) | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5518887A (en) | 1992-03-30 | 1996-05-21 | Abbott Laboratories | Immunoassays empolying generic anti-hapten antibodies and materials for use therein |
| US5795714A (en) | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
| US6087491A (en) * | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
| IT1270951B (it) | 1993-06-07 | 1997-05-26 | Boehringer Mannheim Italia | Metodo e dispositivo per il rilevamento simultano di neisseria gonorrhoeae, chlamydia trachomatis e mycoplasma |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| US5789167A (en) * | 1993-09-10 | 1998-08-04 | Genevue, Inc. | Optical detection of position of oligonucleotides on large DNA molecules |
| US5415839A (en) | 1993-10-21 | 1995-05-16 | Abbott Laboratories | Apparatus and method for amplifying and detecting target nucleic acids |
| US7569341B2 (en) | 1994-01-31 | 2009-08-04 | Trustees Of Boston University | Nucleic acid directed immobilization arrays and methods of assembly |
| US5561043A (en) | 1994-01-31 | 1996-10-01 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
| US5786141A (en) | 1994-08-26 | 1998-07-28 | Bard; Allen J. | Electrogenerated chemiluminescence labels for analysis and/or referencing |
| US5648213A (en) | 1994-08-30 | 1997-07-15 | Beckman Instruments, Inc. | Compositions and methods for use in detection of analytes |
| US5620850A (en) | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
| US5866434A (en) | 1994-12-08 | 1999-02-02 | Meso Scale Technology | Graphitic nanotubes in luminescence assays |
| US5643713A (en) | 1995-06-07 | 1997-07-01 | Liang; Pam | Electrochemiluminescent monitoring of compounds |
| US5641623A (en) | 1995-01-04 | 1997-06-24 | Martin; Mark T. | Electrochemiluminescence assay |
| US6207369B1 (en) | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
| JPH11502617A (ja) | 1995-03-10 | 1999-03-02 | メソ スケール テクノロジーズ，エルエルシー | 多重アレイの多重特異的な電気化学発光試験 |
| US5722553A (en) * | 1995-03-31 | 1998-03-03 | Hovatter; Kenneth P. | Integral assembly of microcentrifuge strip tubes having independently tethered angularly related seal caps |
| US6319670B1 (en) | 1995-05-09 | 2001-11-20 | Meso Scale Technology Llp | Methods and apparatus for improved luminescence assays using microparticles |
| US5679519A (en) | 1995-05-09 | 1997-10-21 | Oprandy; John J. | Multi-label complex for enhanced sensitivity in electrochemiluminescence assay |
| US5589136A (en) | 1995-06-20 | 1996-12-31 | Regents Of The University Of California | Silicon-based sleeve devices for chemical reactions |
| US5723320A (en) | 1995-08-29 | 1998-03-03 | Dehlinger; Peter J. | Position-addressable polynucleotide arrays |
| WO1997014028A2 (en) | 1995-10-11 | 1997-04-17 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
| GB9606850D0 (en) | 1996-04-01 | 1996-06-05 | Univ Liverpool | An assay system and novel labelled compounds for use therwith |
| US6001310A (en) * | 1996-10-11 | 1999-12-14 | Shaffer; John V. | Pliable centrifuge tube array |
| CA2274315A1 (en) | 1996-12-06 | 1998-06-11 | Niels Pallisgaard | Detection of chromosomal abnormalities |
| FR2764381A1 (fr) | 1997-06-09 | 1998-12-11 | Univ De Neuchatel | Detecteur electrochimioluminescent |
| US6413783B1 (en) | 1997-09-18 | 2002-07-02 | Meso Scale Technologies, Llc | Assay sonication apparatus and methodology |
| US6200531B1 (en) | 1998-05-11 | 2001-03-13 | Igen International, Inc. | Apparatus for carrying out electrochemiluminescence test measurements |
| EP0962773A1 (en) | 1998-06-03 | 1999-12-08 | Mark Howard Jones | Electrochemical based assay processes instrument and labels |
| GB9815042D0 (en) | 1998-07-10 | 1998-09-09 | Imperial College | Detector |
| US6214552B1 (en) | 1998-09-17 | 2001-04-10 | Igen International, Inc. | Assays for measuring nucleic acid damaging activities |
| WO2000031536A2 (en) * | 1998-11-23 | 2000-06-02 | President And Fellows Of Harvard College | Detecting structural or synthetic information about chemical compounds |
| US6136268A (en) | 1999-08-17 | 2000-10-24 | Orion Diagnostica | Method for luminescence measurements |
| US20050287592A1 (en) * | 2000-08-29 | 2005-12-29 | Yeda Research And Development Co. Ltd. | Template-dependent nucleic acid polymerization using oligonucleotide triphosphates building blocks |
| US7070740B1 (en) | 2000-09-28 | 2006-07-04 | Beckman Coulter, Inc. | Method and apparatus for processing biomolecule arrays |
| US6601725B2 (en) * | 2001-05-15 | 2003-08-05 | 3088081 Canada, Inc. | Integral assembly of reagent tubes and seal caps |
| DK2423673T3 (da) | 2001-06-29 | 2020-09-07 | Meso Scale Technologies Llc | Indretning til måling af luminescens fra en flerbrønds-assayplade med en flerhed af brønde, fremgangsmåde til måling af luminescens med anvendelse af indretningen og system omfattende indretningen |
| US6942972B2 (en) | 2001-10-24 | 2005-09-13 | Beckman Coulter, Inc. | Efficient synthesis of protein-oligonucleotide conjugates |
| JP4657919B2 (ja) * | 2002-08-19 | 2011-03-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 進化する新しい分子機能 |
| US20040049351A1 (en) * | 2002-08-28 | 2004-03-11 | Matson Robert S. | Immunosorbent assay in microarray format |
| US6913890B2 (en) * | 2002-12-18 | 2005-07-05 | Palo Alto Research Center Incorporated | Process for preparing albumin protein conjugated oligonucleotide probes |
| US7229763B2 (en) | 2003-04-07 | 2007-06-12 | Beckman Coulter, Inc. | Assay system using labeled oligonucleotides |
| US7195875B2 (en) | 2003-04-18 | 2007-03-27 | Beckman Coulter, Inc. | Oligonucleotide pairs for multiplexed binding assays |
| US20040258563A1 (en) * | 2003-06-23 | 2004-12-23 | Applera Corporation | Caps for sample wells and microcards for biological materials |
| JP2005164509A (ja) * | 2003-12-05 | 2005-06-23 | Hitachi High-Technologies Corp | 試薬容器 |
| EP1774033A4 (en) * | 2004-06-10 | 2008-04-23 | Perkinelmer Las Inc | MULTIPLEX ASSAYS FOR DETECTION OF ANALYTES |
| US7704730B2 (en) | 2004-10-14 | 2010-04-27 | Meso Scale Technologies, Llc | Multiplexed assay methods |
| US20060292559A1 (en) | 2005-06-23 | 2006-12-28 | Beckman Coulter, Inc. | Cell-based microarrays, and methods for their preparation and use |
| US7494776B2 (en) | 2005-07-07 | 2009-02-24 | Beckman Coulter, Inc. | Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands |
| KR100927886B1 (ko) * | 2007-06-18 | 2009-11-23 | 한국생명공학연구원 | 단백질 ｇ-올리고 뉴클레오타이드 결합체 |
| WO2009012185A1 (en) * | 2007-07-13 | 2009-01-22 | Handylab, Inc. | Polynucleotide capture materials, and methods of using same |
| JP2010533869A (ja) * | 2007-07-16 | 2010-10-28 | カリフォルニア インスティチュート オブ テクノロジー | 標的分子を検出するためのマイクロ流体装置、方法及びシステム |
| EP2088204A1 (en) * | 2008-02-05 | 2009-08-12 | Adnagen AG | Method and kit for diagnosing or controlling the treatment of ovarian cancer |
| JP2011527903A (ja) * | 2008-07-14 | 2011-11-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 細胞マイクロキャリアのアセンブリを供給するためのプロセス |
| CA2647953A1 (en) | 2008-12-29 | 2010-06-29 | Sqi Diagnostics Systems Inc. | Multiplex analyte detection |
| US20100261292A1 (en) | 2009-04-10 | 2010-10-14 | Meso Scale Technologies, Llc | Methods for Conducting Assays |
| US8480953B2 (en) * | 2009-05-20 | 2013-07-09 | Protedyne Corporation | System and method for vessel alignment |
| US20130184184A1 (en) * | 2010-11-22 | 2013-07-18 | The University Of Chicago | Methods and/or Use of Oligonucleotide Conjugates Having Varied Degrees of Labeling for Assays and Detections |
| US9182334B2 (en) * | 2012-02-24 | 2015-11-10 | Agilent Technologies, Inc. | Method of determining thermodynamic and kinetic parameters from measured off rates |
| JP5926990B2 (ja) * | 2012-03-16 | 2016-05-25 | シスメックス株式会社 | 検体処理装置 |
| US9180461B2 (en) * | 2012-10-22 | 2015-11-10 | Qiagen Gaithersburg, Inc. | Condensation-reducing incubation cover |
| USD703345S1 (en) * | 2012-10-29 | 2014-04-22 | Universal Bio Research Co., Ltd. | Plurality of reaction vessels with lids |
| EP4480582A1 (en) * | 2013-01-18 | 2024-12-25 | Biomeme, Inc. | Analytic device |
| CA2904020C (en) | 2013-03-11 | 2022-06-14 | Meso Scale Technologies, Llc. | Improved methods for conducting multiplexed assays |
| US9802196B2 (en) * | 2013-03-13 | 2017-10-31 | Alphagem Bio Inc. | Ergonomic numbered connector to hold tubes with improved cap |
| JP6387387B2 (ja) * | 2013-03-15 | 2018-09-05 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | プロセスチューブおよび搬送用トレイ |
| US8808650B1 (en) * | 2013-03-15 | 2014-08-19 | Shazi Iqbal | Foldable specimen rack with configurable specimen receiver |
| CA2919833A1 (en) * | 2013-07-30 | 2015-02-05 | President And Fellows Of Harvard College | Quantitative dna-based imaging and super-resolution imaging |
-
2014
- 2014-03-11 CA CA2904020A patent/CA2904020C/en active Active
- 2014-03-11 ES ES14778374T patent/ES2942031T3/es active Active
- 2014-03-11 CN CN201910389701.1A patent/CN110286215A/zh active Pending
- 2014-03-11 EP EP14778374.0A patent/EP2972353B1/en active Active
- 2014-03-11 KR KR1020227036862A patent/KR102746751B1/ko active Active
- 2014-03-11 US US14/203,638 patent/US10189023B2/en active Active
- 2014-03-11 DK DK14778374.0T patent/DK2972353T3/da active
- 2014-03-11 KR KR1020157028300A patent/KR102275006B1/ko active Active
- 2014-03-11 KR KR1020247042210A patent/KR20250002843A/ko active Pending
- 2014-03-11 JP JP2016501106A patent/JP6791750B2/ja active Active
- 2014-03-11 CA CA3153763A patent/CA3153763A1/en active Pending
- 2014-03-11 AU AU2014249190A patent/AU2014249190C1/en active Active
- 2014-03-11 EP EP23157850.1A patent/EP4219750A3/en active Pending
- 2014-03-11 KR KR1020217020789A patent/KR102459433B1/ko active Active
- 2014-03-11 CN CN201480026770.1A patent/CN105378477B9/zh active Active
- 2014-03-11 WO PCT/US2014/022948 patent/WO2014164594A1/en not_active Ceased
-
2015
- 2015-09-08 US US14/847,381 patent/US10413904B2/en active Active
- 2015-09-08 US US14/847,761 patent/US20160069872A1/en not_active Abandoned
-
2017
- 2017-10-16 US US15/784,399 patent/US10201812B2/en not_active Ceased
-
2018
- 2018-12-05 US US16/210,165 patent/US11148145B2/en active Active
- 2018-12-20 US US16/227,081 patent/US11059046B2/en active Active
-
2019
- 2019-09-13 US US16/570,309 patent/US11772098B2/en active Active
-
2020
- 2020-01-30 AU AU2020200675A patent/AU2020200675B2/en active Active
-
2021
- 2021-02-11 US US17/173,898 patent/USRE49774E1/en active Active
- 2021-03-29 US US17/215,962 patent/US11951483B2/en active Active
- 2021-09-16 US US17/476,880 patent/US20210402390A1/en active Pending
-
2022
- 2022-09-19 AU AU2022233771A patent/AU2022233771A1/en active Pending
-
2023
- 2023-08-24 US US18/237,677 patent/US12343726B2/en active Active
-
2024
- 2024-03-06 US US18/597,358 patent/US20240375109A1/en active Pending
-
2025
- 2025-05-28 US US19/220,283 patent/US20250375769A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101208437A (zh) * | 2003-12-12 | 2008-06-25 | 圣路易斯大学 | 检测大分子和其它分析物的生物传感器 |
| CN101952719A (zh) * | 2007-07-27 | 2011-01-19 | 通信改革公司 | 检测测定法及其用途 |
Non-Patent Citations (1)
| Title |
|---|
| CHRISTINA BOOZER ET AL.,: "DNA-Directed Protein Immobilization for Simultaneous Detection of Multiple Analytes by Surface Plasmon Resonance Biosensor", 《ANALYTICAL CHEMISTRY》 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110286215A (zh) | 用于进行多路测定法的改进方法 | |
| US11242570B2 (en) | Co-binder assisted assay methods | |
| CN101144814A (zh) | 应用适配子型试剂检测、鉴定和/或定量化合物的方法 | |
| HK1213048B (en) | Improved methods for conducting multiplexed assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |